Oncolytics Biotech Enters Preliminary Collaboration With The Global Coalition For Adaptive Research
Portfolio Pulse from Benzinga Newsdesk
Oncolytics Biotech has entered a preliminary collaboration with the Global Coalition for Adaptive Research to evaluate pelareorep in treating first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
May 15, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oncolytics Biotech has entered a preliminary collaboration with the Global Coalition for Adaptive Research to evaluate pelareorep in treating first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
The collaboration with a reputable research coalition to evaluate a treatment for a severe form of cancer is likely to be viewed positively by investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100